Graft-versus-host disease (GVHD) remains a major barrier to successful hematopoietic stem cell transplant for patients who lack a matched related donor. Partial T-cell depletion (TCD) of the graft may decrease the risk of severe GVHD with unrelated donors (URD) and partially matched related donors (PMRD) while retaining an antileukemic effect. We analyzed our experience using URD and PMRD for pediatric patients with leukemias from 1990 to 2001. A subgroup of 'matched' URD donor pairs was retrospectively analyzed for high-resolution class I. Partial TCD was accomplished with monoclonal antibody T10B9 or OKT3 and complement. There were 76 URD (45% matched) and 28 PMRD recipients. Event-free survival (EFS) was 38.3%, and overall survival (OS) 45.1% at 3 years. On multivariate analysis, there was no difference in survival based upon marrow source, but nonrelapse mortality was higher with the use of PMRD. Relapse occurred in 6% of ALL patients, and 22.8% of AML/MDS patients. Grades III-IV GVHD was observed in only 6.7% of patients. Partial TCD allows use of matched or mismatched URD, or PMRD with little mortality from GVHD, durable engraftment, and no increase in relapse risk. Bone Marrow Transplantation (2005) 35, 151-158.
Allogeneic hematopoietic stem cell transplant may be curative therapy for children with acute leukemias with very high-risk features, or those who have relapsed, and is the only current curative therapy for children with chronic leukemias. An HLA-identical sibling is the ideal donor, but this option is available for only 25-30% of children.
Alternative hematopoietic stem cell (HSC) sources include unrelated donors (URD), unrelated cord blood, and partially matched related donors (PMRD). The National Marrow Donor Program now has over 5 million potential unrelated donors for hematopoietic stem cells, and yields alternative HSC sources for approximately 70% of patients. The use of PMRD further expands the potential donor pool. However, these alternative donor transplants are associated with increased graft-versus-host disease (GVHD), graft rejection, and slow immune reconstitution.
1-3 T-cell depletion (TCD) may decrease the risk of GVHD, but some studies have shown an increased risk of rejection and relapse due to the loss of the graft vs. leukemia effect. 4, 5 Partial (TCD) may decrease the risk of GVHD, yet allow for engraftment and retention of a graftvs-leukemia effect. We report on our series of children and adolescents with leukemias who underwent alternative donor bone marrow transplants with URD or PMRD bone marrow with partial TCD. During the course of this study, the tissue typing technology rapidly advanced, and a subset of URD recipients was analyzed with these newer methods.
Patients and methods
Partial T-cell depletion was initiated in 1990 at the Children's Hospital of Philadelphia, and all patients who received partial TCD marrow through December 2001 are included in this report. Follow-up is through October 2003. The study was approved by the hospital Institutional Review Board and informed consent given by parent or guardian.
Patients with acute myeloid leukemia (AML) received alternative donor transplant in first remission only if they failed to achieve remission with front-line chemotherapy or had high-risk features including t(9;22) or monosomy 7. Patients with acute lymphoblastic leukemia (ALL) underwent alternative donor BMT in first remission only if they had very high-risk features, including t(9;22) or t (4;11) . Patients with ALL in second remission received alternative donor BMT if they relapsed on therapy or within 1 year of discontinuation of therapy, or had adverse features at the time of relapse, such as change in phenotype.
Histocompatibility testing and criteria for donor selection
Before transplantation, HLA typing on the patient and potential donors included serotyping for HLA-A and -B antigens by the standard NIH two-stage complementdependent cytotoxicity test 6 and high-resolution DNAbased typing for HLA-DRB1 and DQB1 loci. 7 Since 1997, the typing of A and B loci for the patient and unrelated donor was performed by DNA-based low-to-intermediate resolution methods including sequence-specific oligonucleotide probes or sequence-specific primer. 8 Unrelated donor search was performed through the National Marrow Donor Program. A related donor was preferred over an unrelated donor if there was only a single antigen mismatch. A related donor was preferred over a one antigen mismatched unrelated donor if the related donor was matched at DRB1. Haploidentical related donor was utilized only in the absence of a matched, or one antigen mismatched, unrelated donor.
DNA was available for retrospective high-resolution typing of Class I (A, B, C) for 22 URD-patient pairs who were matched by low resolution (serology or DNA-based typing) at the A and B loci, and by high resolution at DRB1 loci. Depending on the low-resolution results, appropriate SSP reactions were chosen (Olerup SSP, Genovision, Inc. for A and B loci, and PelFreez for C locus) for highresolution typing.
Transplantation procedure
All patients were treated in a single room with highefficiency particulate air filtration. Patients received oral antibiotic decontamination with vancomycin or erythromycin and gentamicin. Fluconazole was started at the time of conditioning and continued until discharge. Pneumocystis carinii prophylaxis included clotrimazole prior to BMT, and aerosolized or intravenous pentamidine post BMT until platelets 460 Â 10 8 /kg, at which point prophylactic clotrimazole was restarted. Acyclovir was given until 1-year post BMT. Intravenous gammaglobulin 400 mg/kg was given every other week for 3 months, and then monthly if IgG was o500 ng/dl. In 2000, CMV monitoring was instituted with quantitative antigenemia monitoring weekly. Pre-emptive ganciclovir was given for antigenemia.
Conditioning for the first 60 patients included cytosine arabinoside 3 g/m 2 every 12 h for four doses on days À7, À6 and cyclophosphamide 45 mg/kg for days À5, À4 followed by total-body irradiation 1320 cGy in eight fractions/4 days with shielding of heart, lungs and kidneys for the last two fractions. Six patients received busulfan 4 mg/kg prior to Ara-C and cyclophosphamide. 9 The remaining 44 patients received a protocol which included thiotepa 5 mg/kg on days À7, À6, cyclophosphamide 60 mg/kg for days À5, À4 followed by TBI, 1200 cGy in six fractions, without shielding. Methylprednisolone 1 g/m 2 q 12 h was given for four doses on days À2, À1 and 500 mg/m 2 immediately prior to bone marrow infusion. GVHD prophylaxis included cyclosporine infusion to maintain serum level of 250-400 ng/dl. This was converted to oral formulation when the patient was able to take oral medications.
Cyclosporine was rapidly weaned in the absence of GVHD by 3 months post-BMT.
Partial T-cell depletion
The bone marrow was initially concentrated and partially red cell depleted on the COBE 2991 blood processor (Cobe BCT, Inc., Lakewood, CO, USA). The buffy coat was then separated on density gradients (LSM, ICN International). The mononuclear cell fraction was washed three times in 0.9% sodium chloride with HSA and resuspended in RPMI (Life Technologies) with 10% fetal bovine serum (Hyclone). The bone marrow mononuclear fraction was T-cell depleted with monoclonal antibody (Mab) and complement (C-six Diagnostics) at a final cell concentration of 15 Â 10 6 / ml. The Mab initially used was T10B9. However, since we were unable to obtain this antibody in a form suitable under FDA guidelines, OKT3 (Muromonoab, Orthoclone) was substituted in 2000. The mononuclear cells were first incubated with the antibody at 2-61C on a rotator for 30 min. After the antibody incubation, DNAse (Sigma 4513) was added at 50 U/ml and young rabbit complement added at concentrations ranging from 35 to 50% for 90 min at 371C with gentle agitation on an orbitron rotator. The complement lots were pre-screened in a small-scale Tdepletion test for activity and lack of toxicity to progenitor cells. The cells were washed on the COBE processor with Lactate Ringer's and HSA. Before the last two washes a 5 min incubation with DNAse at 371C was included to breakup any clumps. For the infusion the cells were resuspended in Lactated Ringer's and human serum albumin.
Quality control assays included cell counts and differentials at various steps in the processing, bacterial and fungal cultures and flow cytometric analysis before and after T-cell depletion.
Flow cytometric analysis
Over the course of the study, the methods and instrumentation changed with technology advances. Flow evaluation for CD34 þ and a T-cell panel was performed initially with indirectly conjugated and later with directly conjugated Mab. Different flow cytometers were used: first, the Coulter Epics (Coulter Immunology, Hialeah, FL, USA) 1991-1993 and later Becton Dickinson (B-D, San Jose, CA, USA) instruments, the Elite, the FACSCalibur and finally the FACScan. The T-cell panel included two color CD45-FITC/CD-3PE, three color CD45-PerCP/CD5-PE/CD19-FITC, and CD45-PerCP/CD5-FITC/CD3-PE. The appropriate isotype controls were included with each panel. The antibodies used were either from Pharmigen or from Becton-Dickinson.
Post transplantation evaluation
Engraftment day was the first of 3 consecutive days on which the neutrophil count was X500 ml. Chimerism was documented by variable nucleotide tandem repeats and/or fluorescent in situ hybridization (FISH) for sex mismatch.
Patients with CML had quantitative bcr-abl monitoring by
Partial T-cell depletion of bone marrow for leukemias N Bunin et al polymerase chain reaction every 3 months once they were 6 months post BMT. Patients who engrafted were evaluable for acute GVHD, and patients who survived more than 100 days were evaluable for chronic GVHD. GVHD was graded according to established criteria. 10, 11 Acute GVHD was treated with methylprednisolone or prednisone 1-2 mg/kg and tapered weekly according to response. For patients who did not respond, additional agents were used, including Daclizumab, antithymocyte globulin and mycophenolate mofetil.
Statistical analysis
All statistical analyses were performed in STATA 8.0 (STATA Corp., College Park, TX, USA). The cutoff date for analysis was 11/1/2003. For all patients, an event was defined as relapse or nonrelapse mortality. A donor lymphocyte infusion (DLI) in a CML patient who remained bcr-abl positive was treated as an event. In univariate analysis, a w 2 test was used to compare the proportion of events between two groups and a t-test used to compare means of continuous variables. Kaplan-Meier and Cox Proportional Hazards models were used for survival analysis and multivariable models, respectively. Age was analyzed with a cutoff of 15 years based upon the NMDP ALL experience, in which patients older than 15 years had inferior outcomes. 12 All P-values were two sided. The following factors were considered in the multivariate models: age, type of donor, type of TCD, conditioning regimen, CD34 þ dose, CD3 þ dose, and diagnosis of AML/MDS. Age and cell doses were treated as continuous variables.
Results
Clinical features of the patients are shown in Table 1 . There were three patients with secondary leukemias (two, AML, one, ALL). One patient with AML had received an autologous BMT 1 year prior to UD BMT. Follow-up for surviving patients is from 23 to 139 months (median, 63 months).
Donors
Unrelated donors were utilized for 76 patients, and PMRD for 28. Related donors included siblings (five) and parents (23) . Patient and low-resolution class I HLA data are listed in Table 2 .
For the 22 URD-patient-matched pairs that were retrospectively typed at class I by high-resolution DNAbased typing methods, differences were found in 54%. These included five patients with differences in A or B alleles, six with different C alleles, and one with differences in both B and C alleles. In three patients, the C alleles were mismatched in both loci.
Cell infusion and engraftment
The median number of nucleated cells infused after T-cell depletion was 1 Â 10 8 /kg (range, 0.07-5). The median number of CD3 þ cells/kg was 0.8 Â 10 6 (range, 0.01-18), and CD34 þ cells 2.7 Â 10 6 /kg (0.5-29). There were no differences in the efficiency of TCD between T10B9 and OKT3 (data not shown). Two patients died within 1 week of transplant, and are not eligible for engraftment analysis. All but one patient, with CML, had primary engraftment. An absolute neutrophil count 4500 occurred at a median of 18 days (range, 10-40). Myeloid engraftment occurred at a median of 18.5 days for the 52 patients who received X1 Â 10 8 /kg mononuclear cells, and at a median of 20.1 days for the 48 patients who received o1 Â 10 8 /kg MNC (P ¼ 0.12). Platelet independence was accomplished in 70% of patients, and in these patients, a platelet count X20 Â 10 8 /kg without transfusion was reached at a median of 24 days (9-160).
The CML patient with primary graft failure had a donor that was matched by high resolution at A, B, DRB1, but mismatched at C. He subsequently received additional immunosuppression, and engrafted completely using CD34 þ selected peripheral stem cells from a sister who was matched at B, and haploidentical at other loci. Two patients developed secondary graft failure; in one it was attributed to HHV6 infection. The second patient rejected her A locus incompatible paternal graft (B locus identical by high-resolution typing), and successfully engrafted with maternal haploidentical CD34 þ peripheral stem cells. (Table 3) . Ara-C containing conditioning was associated with inferior OS on univariate analysis, and inferior EFS with a trend for inferior OS on multivariate analysis ( Table 4) . On univariate analysis, severe acute GVHD was significant in determining poor outcome; chronic GVHD was associated with improved EFS, but there was no difference in OS. Increased CD34 þ dose was significantly associated with decreased risk of an event, and increased CD3 þ dose-approached significance for increased event risk on multivariate analysis.
GVHD
The cumulative incidence of acute GVHD grades II-IV was 34% at day 100. Seven patients (6.7%) developed grades III-IV. Three of these seven patients had received OKT3-depleted marrow. Patients who received marrow TCD with OKT3 were at increased risk for both acute and chronic GVHD (Table 5 ). When the dose of CD3 þ cells/kg was evaluated, there was no effect with doses o or 41 or 5 Â 10 6 /kg. Chronic GVHD developed in 45 of 79 evaluable patients, and was limited in 82%. Again, only the type of T-cell depletion had a significant impact upon development of chronic GVHD (Table 5) . Organ involvement for patients with extensive chronic GVHD included skin, lung and oropharynx. In all, 26 of the 27 survivors with chronic GVHD are off all immunosuppression. Death attributable to complications of chronic GVHD occurred in two patients, with bronchiolitis obliterans and sepsis caused by staphylococcus aureus. One surviving patient has a performance score of 90; in the remainder it is 100.
Relapse
There was no difference in relapses between Ara-C and Thiotepa regimens. Eight patients (6%) with ALL relapsed at a median of 227 days (range, 49-519). Of four patients with ALL who received DLI, two achieved complete remission, and remain in remission at 82 and 94 months post-DLI. Eight patients (22.8%) with AML/MDS relapsed at a median of 221 days (range, 103-404). DLI was given to two patients, but was ineffective. One patient with JMML-experienced relapse prior to day 30, but achieved a sustained remission following withdrawal of immunosuppression. Six patients with CML had persistent bcr-abl by quantitative PCR, and FISH positive t(9;22), and five successfully received DLI. One patient did not respond to DLI, and died following a second BMT.
Nonrelapse mortality (NRM)
NRM at day 100 was 22.4% for URD recipients, and 28.6% for PMRD recipients (P ¼ 0.51). However, overall NRM was higher for PMRD recipients, 57.1%, than URD recipients, 34.2% (P ¼ 0.03). Age, type of conditioning or TCD, and CD3 þ dose had no effect upon NRM. A CD34 þ dose of 42 Â 10 6 /kg was associated with lower early NRM (18.1 vs 37.5%, P ¼ 0.03), but there was no beneficial effect upon overall NRM. The subgroup that was completely matched by high resolution had an overall Partial T-cell depletion of bone marrow for leukemias N Bunin et al NRM 8.3 vs 39.3% for those who were mismatched by high-or low resolution (P ¼ 0.04). In the multivariate analysis, only PMRD was associated with increased NRM (Table 4) . Neither infection nor organ toxicity as single causes were more common in PMRD transplants. Causes of NRM are shown in Figure 2 . Infectious deaths included bacterial (4: Strep viridans, Enterobacter, Clostridium difficile, Pseudomonas), HHV6 (1), adenovirus (2), CMV (3), fungus (2), PCP (1). All CMV deaths from pneumonitis occurred before routine antigenemia screening. There were three early deaths related to GVHD and infectious or hemorrhagic complications, and two late deaths related to infection and one from bronchiolitis obliterans. One patient died of complications from autoimmune hemolytic anemia, which has been reported as a complication of T-depleted BMT. 13 Deaths from causes attributable to underlying disease and/or treatment-included AML patients who developed congestive heart failure following anthracyclines and mitoxantrone, and congestive heart failure in a patient with ALL and hypereosinophilic heart disease. Veno-occlusive disease was responsible for deaths in five patients, including one AML patient who had received gemtuzumab.
Epstein-Barr virus lymphoproliferative disorder developed before day 150 in six patients; two patients (2.7%) following URD BMT, and four patients (14%) following PMRD BMT. One patient received DLI, but died from progressive disease, and one patient received DLI and rituximab, but died of complications from GVHD, which developed post DLI. In another patient it was an incidental finding at the time of death from pseudomonas bacteremia.
Discussion
Our results of URD and PMR donor BMT are comparable to results of T-replete URD BMT, 1,14 as well as prior c Ara-C is the reference category.
Table 5
Univariate analysis of factors affecting development of acute and chronic GVHD Acute GVHD n (%) P Chronic GVHD (79 evaluable) Surviving 100 days n (%) P Partial T-cell depletion of bone marrow for leukemias N Bunin et al studies using T-cell depletion. 9 GVHD was responsible for only 5% of deaths in our series, in contrast to studies with T-replete URD BMT in which grades III-IV acute GVHD occur in up to 45% of serologically matched recipients. 3, 14, 15 TCD has been reported to increase the risk of leukemic relapse, and the UK Campath study for ALL noted a relapse rate of 67%. 4 However, our relapse rate was 6% for ALL patients, and 23% for the AML/MDS patients, which is comparable to studies of T-replete URD BMT for pediatric leukemias.
14,15 Although many of our CML patients remained bcr-abl positive by PCR, the majority of these patients were salvaged with DLI, and with limited or no GVHD.
The risks associated with T-cell depletion, such as increased graft rejection, relapse and delayed immune reconstitution, may be highly dependent upon the method and degree of T-cell depletion, as well as intensity of conditioning and post-BMT immunosuppression. Extensive TCD, with three logs or greater reduction, has the advantage of eliminating the need for post-SCT immunosuppression. The increase in graft rejection may be overcome with increased pre-BMT immunosuppression, 5 but this may increase the risks of relapse and EBV lymphomas. With partial TCD, additional immunosuppression post BMT is needed, but can be rapidly weaned in the absence of GVHD. A recent study comparing various methods of TCD and outcome demonstrated that the use of narrow specificity antibodies, such as we used, was associated with superior leukaemia-free survival compared with other TCD methods. However, there was no difference in survival when compared to T-replete grafts. 16 This study included the use of multiple HLA disparate donors, which may account for this finding. This type of donor generally would have been used only by centers utilizing TCD. For partial TCD, we initially used T10B9, an IgM monoclonal antibody in use for more than 15 years. 17 When T10B9 became unavailable, OKT3 was substituted based upon other reports of its efficacy in haploidentical BMT. However, a recent report demonstrated a significantly higher incidence of acute GVHD with OKT3 compared to T10B9 BMT recipients. 18 This increased risk of GVHD resulted in the addition of post-BMT ATG, with a subsequent increase in EBV lymphomas.
The technology of HLA typing underwent major changes during the course of this study. We found that 54% of serologically matched pairs in an URD-patient subset were mismatched at one or more class I loci when typed by highresolution methods, which is consistent with other studies. 19, 20 However, the clinical importance of these mismatches is not defined in the context of partial TCD. Some studies have shown that in the T-replete setting, more precise characterization and matching of class I alleles may decrease GVHD and graft rejection, and increase survival. 21 Although high-resolution matching of classes I and II may decrease the risk of certain BMT complications with T-replete stem cells, it will also limit donor availability. In contrast to other studies, we found no significant differences in EFS, GVHD or NRM between our URD recipients who were matched vs those who were mismatched. Although children may tolerate HLA disparity better than older patients in the T-replete setting, there is still an increased risk of NRM. 1, 22 It is difficult to fully evaluate the effects of high-resolution matching in our study. Practice changes made during the time period of high-resolution typing also may have impacted upon outcome. Conditioning was changed from Ara-C to thiotepa, which was associated with superior outcome, and the method of T depletion changed from T10B9 to OKT3. Thus, the benefits of high-resolution matching with URD SCT and partial TCD need to be confirmed in a larger, prospective setting.
The incidence of graft failure was extremely low in our series. Although escalation of TBI dose has been proposed to ensure immunosuppression and engraftment in TCD BMT, many patients engrafted with 1200 cGy, and it was not essential to expose children to increased risks of organ toxicity from higher doses. Additional agents with cyclophosphamide, such as cytarabine and thiotepa, both of which are immunosuppressive, also may facilitate engraftment. Our only primary graft failure occurred in a patient with CML, but this may have been based upon the disparity at the C locus, which is recognized as increasing the risk of rejection in CML patients. 23 None of the other patients mismatched at C rejected their grafts. Secondary graft failure occurred in two patients with ALL, and in one patient was associated with HHV 6 infection, which is recognized as causing bone marrow suppression. 24 NRM, not related to GVHD, remains a large barrier to survival post alternative donor BMT. Patients with acute leukemias, who comprise the bulk of pediatric leukemia transplants, are generally heavily pre-treated following relapse. Newer protocols, incorporating cardiotoxic agents, such as mitoxantrone, or gemtuzumab, which increases the risk of VOD, 25 were used for some of our patients. Highdose cytarabine added for increased immunosuppression and antileukemic effect may increase the risk of pulmonary toxicity. 26 Although nonmyeloablative regimens are less toxic, their efficacy for acute pediatric leukemias is untested, particularly in the context of partially T-depleted grafts. On multivariate analysis we noted decreased NRM and increased EFS with the thiotepa regimen. Thiotepa has an advantage in being a novel agent for patients, as it is generally not included in relapse chemotherapy protocols due to its profound myelosuppression, and it has excellent CNS penetration.
The use of PMRD with TCD has been found to be successful for many patients for whom an unrelated donor cannot be found as quickly as needed. 27, 28 The study by Godder et al 28 noted slightly less GVHD, 24%, than in our study, but this is probably accounted for by the 12-day course of ATG given post BMT. In our study, we noted a higher overall NRM in recipients of PMRD compared to those of URD donors, but no difference in outcomes. In contrast, the study by Drobyski et al, 29 compared recipients of matched and mismatched URD and PMRD. Recipients of matched URD had a superior survival (58%) to either mismatched URD (34%) or haploidentical recipients (21%). NRM was significantly higher in recipients of mismatched URD and haploidentical grafts (45 and 42%), compared to matched URD (23%). Our study population differs from theirs in the younger median age, and fewer patients with CML. Although URD and PMRD recipients had similar outcomes, we found a higher NRM between UD and PMR recipients in both the univariate and multivariate analyses. Therefore, we would not preferentially use a 41 antigen-mismatched related donor over a one antigen or allele-mismatched URD. Haploidentical peripheral stem cell transplant is also an alternative, but delayed immune recovery with a significant risk of viral infections remains a concern. 30 Cord blood has become a significant source of alternative stem cells, with the development of larger regional donor banks and similar outcomes in children. During the course of much of this study, however, cord blood banks were very limited and not unified within the NMDP. Although GVHD is decreased with HLA disparity in cord bloods, graft failure remains higher than with TCD BM. 31 The use of cord blood also does not permit later donor lymphocyte infusions, which may be utilized successfully for some relapsed patients with both chronic and acute leukemia.
Each alternative HSC source, unrelated donor marrow or peripheral blood cells, unrelated cord blood, and partially matched related donor, has potential advantages and disadvantages. Therefore, a donor for a child in need of a HSCT should be considered on an individual basis. Obvious advantages with PMRD and unrelated cord blood is the shorter time to procurement. However, it is our policy to require patients to achieve a remission, and in the case of ALL, to sustain remission for at least several months to reduce leukemic burden. Patients with AML are also required to be in remission, and remission induction is followed by an abbreviated repetition of their reinduction therapy. This time is used to locate and activate an unrelated donor. Our approach may select for better risk patients, but we do not transplant patients in relapse, and all patients who achieved remission were able to proceed to transplant. Only a few cord blood transplants were performed during this period for leukemias due to the lateness of the referral. We recommend early referral for identification of an alternate donor, as it may take several months. Partial TCD allows use of donors that might be otherwise unsuitable due to the risks of severe GVHD, and the risk of relapse does not appear increased. Expansion of the donor pool to include mismatched URD or PMRD allows transplantation for patients for whom a fully matched donor is unavailable.
